Santosh Vetticaden ready for Adventrx as CMO
This article was originally published in Scrip
Biopharmaceutical company Adventrx Pharmaceuticals has appointed Dr Santosh Vetticaden chief medical officer and senior vice-president. Dr Vetticaden most recently served as senior vice-president and chief medical and development officer at Cubist Pharmaceuticals.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.